Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar User Fee Negotiations Under Way; Timetable Compressed

Executive Summary

FDA has started biosimilar user fee negotiations with industry, although it does not appear the room is overcrowded with participants.

You may also be interested in...



Biosimilar User Fee Talks Begin With Industry Negotiating Amongst Itself

FDA asks negotiators from the four industry groups to coordinate proposed changes as BsUFA renewal talks get underway.

Biosimilars Forum: How Do You Create A Brand-Generic Coalition? Don’t Talk About Naming

Group of 11 companies is focusing on biosimilar reimbursement and educational issues important to market formation.

Biosimilar User Fee Agreement Reached, But Will Require Appropriations Boost

Tentative agreement closely resembles FDA's original proposal.

Related Content

Topics

UsernamePublicRestriction

Register

PS053548

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel